CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zealand Pharma A/S is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zealand Pharma A/S
Sydmarken 11
Phone: +45 88773600p:+45 88773600 SOEBORG, 2860  Denmark Ticker: ZEALZEAL
Business Summary
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Alf G.Nicklasson 69 4/21/2015 4/21/2015
President, Chief Executive Officer, Member of the Executive Management Adam S.Steensberg 50 3/30/2022 3/19/2015
Independent Vice Chairman of the Board Kirsten A.Drejer 68 4/4/2019 4/19/2018
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Valeritas Holdings, Inc. 750 US Highway 202 Bridgewater NJ United States
Valeritas, Inc. 750 US Highway 202 Ste 600 BRIDGEWATER NJ United States

Business Names
Business Name
0NZU
Encycle Therapeutics Inc.
Valeritas, Inc.
10 additional Business Names available in full report.

General Information
Number of Employees: 298 (As of 9/30/2024)
Outstanding Shares: 70,647,067 (As of 9/30/2024)
Shareholders: 36,798
Stock Exchange: CPH
Fax Number: +45 88773898


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024